Summary
Market Overview:
The global anti-venom market size reached US$ 1,096.1 Million in 2022. Looking forward, the analyst expects the market to reach US$ 1,644.9 Million by 2028, exhibiting a growth rate (CAGR) of 6.7% during 2023-2028.
Anti-venoms are purified antibodies used to stop snake venom from binding to tissues and causing severe allergic reactions, blood-clotting, muscle injury, or nervous system problems. They can prevent or reverse the snakebite envenoming effects, which help minimize mortality and morbidity. They are obtained from different animal species, such as snakes, funnel web spiders, stonefish, redback spiders, and box jellyfish, using different technologies. Presently, the type of anti-venom generally used depends on the history and examination of the patient and geographic, clinical, and pathologic factors.
Anti-Venom Market Trends:
The risk of snakebite envenoming is a public health hazard that people, especially in the rural areas, experience on a regular basis. It causes occupational injury among several agricultural workers and hunters, which represents one of the key factors driving the need for safe, effective, and affordable anti-venoms. In addition, open-plan housing and the practice of sleeping on the floor, common in tropical regions, can expose people to bites from nocturnal and highly venomous snakes and cause serious health problems. These health problems usually include kidney failure, severe paralysis that prevents breathing, bleeding disorders that can lead to fatal hemorrhage, and severe local tissue destruction that can cause permanent disability and result in limb amputation. This, in turn, is catalyzing the demand for anti-venoms across the globe. Apart from this, there is an introduction of snake venom detection kits with a rapid enzyme immunoassay for in vitro detection and immunological identification of snake venom in samples from bite sites, urine, plasma, blood, or other tissues and body fluids. This is anticipated to offer lucrative growth opportunities to industry players and drive the overall market.
Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the global anti-venom market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on species, anti-venom type, mode of action and end user.
Breakup by Species:
Snake
Scorpion
Spider
Others
Breakup by Anti-venom Type:
Polyvalent Anti-venom
Monovalent Anti-venom
Breakup by Mode of Action:
Cytotoxic
Neurotoxic
Haemotoxic
Cardiotoxic
Myotoxic
Others
Breakup by End User:
Hospitals
Clinics
Ambulatory Surgical Centers
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc. and Rare Disease Therapeutics Inc.
Key Questions Answered in This Report:
What was the size of the global anti-venom market in 2022?
What is the expected growth rate of the global anti-venom market during 2023-2028?
What has been the impact of COVID-19 on the global anti-venom market?
What are the key factors driving the global anti-venom market?
What is the breakup of the global anti-venom market based on the species?
What is the breakup of the global anti-venom market based on the anti-venom type?
What is the breakup of the global anti-venom market based on the mode of action?
What is the breakup of the global anti-venom market based on the end user?
What are the key regions in the global anti-venom market?
Who are the key players/companies in the global anti-venom market?
